Johnson & Johnson $JNJ Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,910,996 shares of the company’s stock after selling 31,512 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Johnson & Johnson were worth $1,247,240,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Security National Bank of Sioux City Iowa IA grew its position in Johnson & Johnson by 27.2% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 18,143 shares of the company’s stock worth $4,608,000 after purchasing an additional 3,878 shares during the last quarter. Reynders McVeigh Capital Management LLC raised its holdings in shares of Johnson & Johnson by 0.7% in the second quarter. Reynders McVeigh Capital Management LLC now owns 76,513 shares of the company’s stock valued at $19,432,000 after buying an additional 499 shares during the last quarter. Bullseye Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $63,000. Talon Private Wealth LLC grew its holdings in shares of Johnson & Johnson by 89.5% during the second quarter. Talon Private Wealth LLC now owns 10,588 shares of the company’s stock worth $2,689,000 after buying an additional 5,002 shares during the last quarter. Finally, U S Wealth Group LLC. increased its position in Johnson & Johnson by 15.1% in the 2nd quarter. U S Wealth Group LLC. now owns 17,259 shares of the company’s stock valued at $4,383,000 after acquiring an additional 2,266 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $0.18 during trading hours on Wednesday, reaching $269.01. 6,371,746 shares of the company’s stock were exchanged, compared to its average volume of 8,034,880. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company’s 50 day moving average is $264.30 and its two-hundred day moving average is $247.03. The company has a market cap of $648.28 billion, a P/E ratio of 31.17, a price-to-earnings-growth ratio of 2.57 and a beta of 0.24. Johnson & Johnson has a 1 year low of $175.74 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the previous year, the business earned $2.77 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 87,569 shares of company stock valued at $23,064,544. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Guggenheim increased their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a report on Wednesday, July 15th. Royal Bank Of Canada lifted their price objective on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. TD Cowen boosted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $274.13.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination estimated that approximately 87% of eligible relapsed/refractory multiple myeloma patients could reach mortality risk comparable to the general population. The analysis also projected nearly four times longer median survival versus standard care, supporting the long-term commercial potential of J&J’s oncology portfolio. MajesTEC-3 analysis
• Positive Sentiment: J&J’s recently approved ICOTYDE psoriasis treatment expands its immunology growth pipeline beyond oncology and MedTech. Its ongoing Phase 3 psoriatic arthritis program could provide an additional growth opportunity as STELARA sales decline after loss of exclusivity. ICOTYDE immunology push
• Positive Sentiment: Positive Phase 3 results for CAPLYTA in bipolar I mania strengthen the case that J&J’s Intra-Cellular acquisition can broaden the drug’s use beyond bipolar depression. Approval and commercial execution remain future catalysts. CAPLYTA bipolar study
• Neutral Sentiment: Analysts continue to favor J&J’s dividend durability and diversified pipeline, but the stock’s strong 12-month performance and elevated valuation may already reflect much of the expected improvement. Healthcare dividend roundup
• Negative Sentiment: Investor debate remains focused on whether portfolio streamlining, including a potential sale of the orthopedics business, can accelerate growth without sacrificing scale or future MedTech opportunities. The market’s reaction to OTTAVA also underscores the need for stronger execution in MedTech. Potential orthopedics divestiture

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.